November 2018 Volume 14, Issue 11
Volume 14, Issue 11 | November 2018
November 2018
In this Issue
Discovery
ProMIS tackles Parkinson's and Alzheimer’s diseases
Company has high hopes for antibody candidates targeting toxic oligomersRepurposing for neglected diseases
Data collection of existing small-molecule drugs could expedite potential therapiesThe promise of retinoic acid signaling
Research team publishes research on the anticancer effects of retinoic acid on cancer stem cellsBiological engineers discover new antibiotic candidates
Screen of human proteins by MIT researchers reveals some with antimicrobial powerAn ion channel drug discovery
Metrion Biosciences awarded funding under Innovate UK Biomedical Catalyst Primer AwardResearch & Development
Themis pursues oncolytic virotherapies with Max-Planck
Themis Bioscience plans to expand measles vector immunomodulation portfolio into oncology indicationsGene, drug and environment interactions
New modeling provides a more accurate analysis of complex genetic and drug/environment dataBiomarkers for autism
QBM-001 for non-verbal children set for clinical trials in 2019It’s just an expression
Multicenter research team hopes modeling gene expression will answer questions about diseasesAttacking substance use disorder
BioCorRx, forms deal with VDM Biochemicals for opioid antagonistClinical Trials
Recruitment in the digital age
Study reveals that ‘traditional digital advertising rules don’t apply’ in clinical trial recruitmentAttaining adhesion
KB103 yields functional collagen production and sustained wound healing in chronic blistering patientsTherapy triumph
DNA immunotherapy and checkpoint inhibitor combination lead to remissionOut of the starting gate
A roundup of clinical trial startups and progressionsSpecial Reports
Special Report on Molecular Diagnostics: Prenatal probing
Cancer characterization breakthroughs lead to advances in understanding of and techniques for fetal monitoringEditor's Focus
Editor’s focus: The balance between ROI and R&D
Are price controls the best way to rein in drug costs, or do we perhaps need to dig deeper into the issue of what is required to bring drugs to market to begin with?Commentary
Out of order: Beyond the bubble
There is an increasing shift with pharma/biotech researchers and execs not just speaking about platforms and performance but also focusing more intently on people and impacts on daily livesGuest Commentary: The right way to use genetic information in clinical trials
When differences in genetic variants are accounted for in clinical trial design, interventional trials can become much more successful for particular patient groupsFeature
Focus Feature on CRISPR: Deals advance CRISPR technology
Companies and academic institutions work together to unlock cellular reprogramming, single cell RNAseq-linked screening, stem cell-derived therapies for diabetes, engineered mammalian cell lines and moreShow Preview for ASCB/EMBO 2018: Twice as nice
ASCB and EMBO host their second collaborative meeting focused on cell biologyQ&A
Q&A: New standards for IPF
Dr. Wim Wuyts of University Hospitals Leuven discusses with DDNews how updated guidelines for diagnosing IPF offer physicians more clarity, and how Genentech's Esbriet was found to improve lung function in IPF patientsContract Services
CrownBio expands model options in cancer and more
Company completes validation of prostate cancer PDX model and forms alliance with Shanghai Model Organisms CenterCMOs to benefit from double-digit approvals for ADCs
CPhI Annual Report predicts that therapeutic ADC market will reach $4 billion by 2023Global CRO signs agreement with OmniComm Systems
Seven-year TrialOne agreement expands commitment to supporting early-phase studiesDiagnostics
Biogen boosts multiple sclerosis research
Evidence supports serum neurofilament light as useful biomarker; Biogen and Siemens to develop blood testTargeted TMB assessment
MolecularMD validates Thermo Fisher assay that can help in trial stratificationUC Davis and NeuroPointDX to launch biomarker panel
New test will target autism diagnosis for children as young as 18 monthsBusiness & Government Policy
Phase II SBIR grant awarded to Celldom
Money supports advancing tech to process phenotypic and genotypic cell data at massive scaleTargets acquired
A look at some recent M&A and licensing deals in the pharma/biotech worldOn the cutting edge
A roundup of instrumentation, software and other tools and technology newsPatent Docs: Obviousness remains uncertain patentability standard
Public policy regarding innovator drug products need regulatory exclusivities outside mere patent protection in order to provide necessary incentive for further pharmaceutical innovationPreclinical
And the sheep shall lead them...
Day-blind sheep bring potential relief for human eye conditions into focusPossible FOP therapy shines in preclinical study
BLU-782 offers hope for patients with difficult-to-target genetic disease that turns muscle to boneOf antigens and antitumor effects
Preclinical efficacy data of Apogenix’s HERA-CD40L published in Journal of ImmunotherapyStarving tumors
Moleculin announces new data discovery for presentation at Society for Neuro-Oncology meetingAblexis inks licensing deal with Memorial Sloan Kettering
Agreement grants rights to research, develop and commercialize antibodies generated using AlivaMab Mouse platform
Subscribe to our eNewsletters
Stay connected with all of the latest from Drug Discovery News.
SubscribeSponsored
Reliable fluid biomarkers strategies for clinical neuroscience research
Explore how validated fluid biomarker assays advance clinical research for neurological diseases.
Understanding drug impurities: types, sources, and analytical strategies
Unseen and often unexpected, drug impurities can slip in at every drug development stage, making their detection and control essential.
Discovering cutting-edge nitrosamine analysis in pharmaceuticals
New tools help researchers detect and manage harmful nitrosamine impurities in drugs such as monoclonal antibodies.
